1 Report Overview 1.1 Study Scope 1.2 Market Analysis by Type 1.2.1 Global Direct-acting Antiviral Drugs Market Size Growth Rate by Type: 2016 VS 2021 VS 2027 1.2.2 NS3/4A Protease Inhibitors 1.2.3 Nucleoside and Nucleotide NS5B Polymerase Inhibitors 1.2.4 NS5A Inhibitors 1.2.5 Non-Nucleoside NS5B Polymerase Inhibitors 1.3 Market by Application 1.3.1 Global Direct-acting Antiviral Drugs Market Share by Application: 2016 VS 2021 VS 2027 1.3.2 Hospitals 1.3.3 Clinics 1.3.4 Ambulatory Surgical Centers 1.3.5 Pharmacies 1.3.6 Others 1.4 Study Objectives 1.5 Years Considered 2 Global Growth Trends 2.1 Global Direct-acting Antiviral Drugs Market Perspective (2016-2027) 2.2 Direct-acting Antiviral Drugs Growth Trends by Regions 2.2.1 Direct-acting Antiviral Drugs Market Size by Regions: 2016 VS 2021 VS 2027 2.2.2 Direct-acting Antiviral Drugs Historic Market Share by Regions (2016-2021) 2.2.3 Direct-acting Antiviral Drugs Forecasted Market Size by Regions (2022-2027) 2.3 Direct-acting Antiviral Drugs Industry Dynamic 2.3.1 Direct-acting Antiviral Drugs Market Trends 2.3.2 Direct-acting Antiviral Drugs Market Drivers 2.3.3 Direct-acting Antiviral Drugs Market Challenges 2.3.4 Direct-acting Antiviral Drugs Market Restraints 3 Competition Landscape by Key Players 3.1 Global Top Direct-acting Antiviral Drugs Players by Revenue 3.1.1 Global Top Direct-acting Antiviral Drugs Players by Revenue (2016-2021) 3.1.2 Global Direct-acting Antiviral Drugs Revenue Market Share by Players (2016-2021) 3.2 Global Direct-acting Antiviral Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 3.3 Players Covered: Ranking by Direct-acting Antiviral Drugs Revenue 3.4 Global Direct-acting Antiviral Drugs Market Concentration Ratio 3.4.1 Global Direct-acting Antiviral Drugs Market Concentration Ratio (CR5 and HHI) 3.4.2 Global Top 10 and Top 5 Companies by Direct-acting Antiviral Drugs Revenue in 2020 3.5 Direct-acting Antiviral Drugs Key Players Head office and Area Served 3.6 Key Players Direct-acting Antiviral Drugs Product Solution and Service 3.7 Date of Enter into Direct-acting Antiviral Drugs Market 3.8 Mergers & Acquisitions, Expansion Plans 4 Direct-acting Antiviral Drugs Breakdown Data by Type 4.1 Global Direct-acting Antiviral Drugs Historic Market Size by Type (2016-2021) 4.2 Global Direct-acting Antiviral Drugs Forecasted Market Size by Type (2022-2027) 5 Direct-acting Antiviral Drugs Breakdown Data by Application 5.1 Global Direct-acting Antiviral Drugs Historic Market Size by Application (2016-2021) 5.2 Global Direct-acting Antiviral Drugs Forecasted Market Size by Application (2022-2027) 6 North America 6.1 North America Direct-acting Antiviral Drugs Market Size (2016-2027) 6.2 North America Direct-acting Antiviral Drugs Market Size by Type 6.2.1 North America Direct-acting Antiviral Drugs Market Size by Type (2016-2021) 6.2.2 North America Direct-acting Antiviral Drugs Market Size by Type (2022-2027) 6.2.3 North America Direct-acting Antiviral Drugs Market Size by Type (2016-2027) 6.3 North America Direct-acting Antiviral Drugs Market Size by Application 6.3.1 North America Direct-acting Antiviral Drugs Market Size by Application (2016-2021) 6.3.2 North America Direct-acting Antiviral Drugs Market Size by Application (2022-2027) 6.3.3 North America Direct-acting Antiviral Drugs Market Size by Application (2016-2027) 6.4 North America Direct-acting Antiviral Drugs Market Size by Country 6.4.1 North America Direct-acting Antiviral Drugs Market Size by Country (2016-2021) 6.4.2 North America Direct-acting Antiviral Drugs Market Size by Country (2022-2027) 6.4.3 United States 6.4.4 Canada 7 Europe 7.1 Europe Direct-acting Antiviral Drugs Market Size (2016-2027) 7.2 Europe Direct-acting Antiviral Drugs Market Size by Type 7.2.1 Europe Direct-acting Antiviral Drugs Market Size by Type (2016-2021) 7.2.2 Europe Direct-acting Antiviral Drugs Market Size by Type (2022-2027) 7.2.3 Europe Direct-acting Antiviral Drugs Market Size by Type (2016-2027) 7.3 Europe Direct-acting Antiviral Drugs Market Size by Application 7.3.1 Europe Direct-acting Antiviral Drugs Market Size by Application (2016-2021) 7.3.2 Europe Direct-acting Antiviral Drugs Market Size by Application (2022-2027) 7.3.3 Europe Direct-acting Antiviral Drugs Market Size by Application (2016-2027) 7.4 Europe Direct-acting Antiviral Drugs Market Size by Country 7.4.1 Europe Direct-acting Antiviral Drugs Market Size by Country (2016-2021) 7.4.2 Europe Direct-acting Antiviral Drugs Market Size by Country (2022-2027) 7.4.3 Germany 7.4.4 France 7.4.5 U.K. 7.4.6 Italy 7.4.7 Russia 7.4.8 Nordic 8 Asia-Pacific 8.1 Asia-Pacific Direct-acting Antiviral Drugs Market Size (2016-2027) 8.2 Asia-Pacific Direct-acting Antiviral Drugs Market Size by Type 8.2.1 Asia-Pacific Direct-acting Antiviral Drugs Market Size by Type (2016-2021) 8.2.2 Asia-Pacific Direct-acting Antiviral Drugs Market Size by Type (2022-2027) 8.2.3 Asia-Pacific Direct-acting Antiviral Drugs Market Size by Type (2016-2027) 8.3 Asia-Pacific Direct-acting Antiviral Drugs Market Size by Application 8.3.1 Asia-Pacific Direct-acting Antiviral Drugs Market Size by Application (2016-2021) 8.3.2 Asia-Pacific Direct-acting Antiviral Drugs Market Size by Application (2022-2027) 8.3.3 Asia-Pacific Direct-acting Antiviral Drugs Market Size by Application (2016-2027) 8.4 Asia-Pacific Direct-acting Antiviral Drugs Market Size by Region 8.4.1 Asia-Pacific Direct-acting Antiviral Drugs Market Size by Region (2016-2021) 8.4.2 Asia-Pacific Direct-acting Antiviral Drugs Market Size by Region (2022-2027) 8.4.3 China 8.4.4 Japan 8.4.5 South Korea 8.4.6 Southeast Asia 8.4.7 India 8.4.8 Australia 9 Latin America 9.1 Latin America Direct-acting Antiviral Drugs Market Size (2016-2027) 9.2 Latin America Direct-acting Antiviral Drugs Market Size by Type 9.2.1 Latin America Direct-acting Antiviral Drugs Market Size by Type (2016-2021) 9.2.2 Latin America Direct-acting Antiviral Drugs Market Size by Type (2022-2027) 9.2.3 Latin America Direct-acting Antiviral Drugs Market Size by Type (2016-2027) 9.3 Latin America Direct-acting Antiviral Drugs Market Size by Application 9.3.1 Latin America Direct-acting Antiviral Drugs Market Size by Application (2016-2021) 9.3.2 Latin America Direct-acting Antiviral Drugs Market Size by Application (2022-2027) 9.3.3 Latin America Direct-acting Antiviral Drugs Market Size by Application (2016-2027) 9.4 Latin America Direct-acting Antiviral Drugs Market Size by Country 9.4.1 Latin America Direct-acting Antiviral Drugs Market Size by Country (2016-2021) 9.4.2 Latin America Direct-acting Antiviral Drugs Market Size by Country (2022-2027) 9.4.3 Mexico 9.4.4 Brazil 10 Middle East & Africa 10.1 Middle East & Africa Direct-acting Antiviral Drugs Market Size (2016-2027) 10.2 Middle East & Africa Direct-acting Antiviral Drugs Market Size by Type 10.2.1 Middle East & Africa Direct-acting Antiviral Drugs Market Size by Type (2016-2021) 10.2.2 Middle East & Africa Direct-acting Antiviral Drugs Market Size by Type (2022-2027) 10.2.3 Middle East & Africa Direct-acting Antiviral Drugs Market Size by Type (2016-2027) 10.3 Middle East & Africa Direct-acting Antiviral Drugs Market Size by Application 10.3.1 Middle East & Africa Direct-acting Antiviral Drugs Market Size by Application (2016-2021) 10.3.2 Middle East & Africa Direct-acting Antiviral Drugs Market Size by Application (2022-2027) 10.3.3 Middle East & Africa Direct-acting Antiviral Drugs Market Size by Application (2016-2027) 10.4 Middle East & Africa Direct-acting Antiviral Drugs Market Size by Country 10.4.1 Middle East & Africa Direct-acting Antiviral Drugs Market Size by Country (2016-2021) 10.4.2 Middle East & Africa Direct-acting Antiviral Drugs Market Size by Country (2022-2027) 10.4.3 Turkey 10.4.4 Saudi Arabia 10.4.5 UAE 11 Key Players Profiles 11.1 AbbVie Inc. 11.1.1 AbbVie Inc. Company Details 11.1.2 AbbVie Inc. Business Overview 11.1.3 AbbVie Inc. Direct-acting Antiviral Drugs Introduction 11.1.4 AbbVie Inc. Revenue in Direct-acting Antiviral Drugs Business (2016-2021) 11.1.5 AbbVie Inc. Recent Development 11.2 GSK 11.2.1 GSK Company Details 11.2.2 GSK Business Overview 11.2.3 GSK Direct-acting Antiviral Drugs Introduction 11.2.4 GSK Revenue in Direct-acting Antiviral Drugs Business (2016-2021) 11.2.5 GSK Recent Development 11.3 Boehringer Ingelheim 11.3.1 Boehringer Ingelheim Company Details 11.3.2 Boehringer Ingelheim Business Overview 11.3.3 Boehringer Ingelheim Direct-acting Antiviral Drugs Introduction 11.3.4 Boehringer Ingelheim Revenue in Direct-acting Antiviral Drugs Business (2016-2021) 11.3.5 Boehringer Ingelheim Recent Development 11.4 Merck 11.4.1 Merck Company Details 11.4.2 Merck Business Overview 11.4.3 Merck Direct-acting Antiviral Drugs Introduction 11.4.4 Merck Revenue in Direct-acting Antiviral Drugs Business (2016-2021) 11.4.5 Merck Recent Development 11.5 Novartis 11.5.1 Novartis Company Details 11.5.2 Novartis Business Overview 11.5.3 Novartis Direct-acting Antiviral Drugs Introduction 11.5.4 Novartis Revenue in Direct-acting Antiviral Drugs Business (2016-2021) 11.5.5 Novartis Recent Development 11.6 Beximco Pharmaceuticals 11.6.1 Beximco Pharmaceuticals Company Details 11.6.2 Beximco Pharmaceuticals Business Overview 11.6.3 Beximco Pharmaceuticals Direct-acting Antiviral Drugs Introduction 11.6.4 Beximco Pharmaceuticals Revenue in Direct-acting Antiviral Drugs Business (2016-2021) 11.6.5 Beximco Pharmaceuticals Recent Development 11.7 Roche 11.7.1 Roche Company Details 11.7.2 Roche Business Overview 11.7.3 Roche Direct-acting Antiviral Drugs Introduction 11.7.4 Roche Revenue in Direct-acting Antiviral Drugs Business (2016-2021) 11.7.5 Roche Recent Development 11.8 Bristol-Myers Squibb Company 11.8.1 Bristol-Myers Squibb Company Company Details 11.8.2 Bristol-Myers Squibb Company Business Overview 11.8.3 Bristol-Myers Squibb Company Direct-acting Antiviral Drugs Introduction 11.8.4 Bristol-Myers Squibb Company Revenue in Direct-acting Antiviral Drugs Business (2016-2021) 11.8.5 Bristol-Myers Squibb Company Recent Development 11.9 Gilead Sciences 11.9.1 Gilead Sciences Company Details 11.9.2 Gilead Sciences Business Overview 11.9.3 Gilead Sciences Direct-acting Antiviral Drugs Introduction 11.9.4 Gilead Sciences Revenue in Direct-acting Antiviral Drugs Business (2016-2021) 11.9.5 Gilead Sciences Recent Development 11.10 Janssen (Johnson & Johnson) 11.10.1 Janssen (Johnson & Johnson) Company Details 11.10.2 Janssen (Johnson & Johnson) Business Overview 11.10.3 Janssen (Johnson & Johnson) Direct-acting Antiviral Drugs Introduction 11.10.4 Janssen (Johnson & Johnson) Revenue in Direct-acting Antiviral Drugs Business (2016-2021) 11.10.5 Janssen (Johnson & Johnson) Recent Development 11.11 Vertex Pharmaceuticals 11.11.1 Vertex Pharmaceuticals Company Details 11.11.2 Vertex Pharmaceuticals Business Overview 11.11.3 Vertex Pharmaceuticals Direct-acting Antiviral Drugs Introduction 11.11.4 Vertex Pharmaceuticals Revenue in Direct-acting Antiviral Drugs Business (2016-2021) 11.11.5 Vertex Pharmaceuticals Recent Development 11.12 Natco Pharma 11.12.1 Natco Pharma Company Details 11.12.2 Natco Pharma Business Overview 11.12.3 Natco Pharma Direct-acting Antiviral Drugs Introduction 11.12.4 Natco Pharma Revenue in Direct-acting Antiviral Drugs Business (2016-2021) 11.12.5 Natco Pharma Recent Development 12 Analyst's Viewpoints/Conclusions 13 Appendix 13.1 Research Methodology 13.1.1 Methodology/Research Approach 13.1.2 Data Source 13.2 Disclaimer 13.3 Author Details

List of Tables Table 1. Global Direct-acting Antiviral Drugs Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027 Table 2. Key Players of NS3/4A Protease Inhibitors Table 3. Key Players of Nucleoside and Nucleotide NS5B Polymerase Inhibitors Table 4. Key Players of NS5A Inhibitors Table 5. Key Players of Non-Nucleoside NS5B Polymerase Inhibitors Table 6. Global Direct-acting Antiviral Drugs Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027 Table 7. Global Direct-acting Antiviral Drugs Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027 Table 8. Global Direct-acting Antiviral Drugs Market Size by Regions (2016-2021) & (US$ Million) Table 9. Global Direct-acting Antiviral Drugs Market Share by Regions (2016-2021) Table 10. Global Direct-acting Antiviral Drugs Forecasted Market Size by Regions (2022-2027) & (US$ Million) Table 11. Global Direct-acting Antiviral Drugs Market Share by Regions (2022-2027) Table 12. Direct-acting Antiviral Drugs Market Trends Table 13. Direct-acting Antiviral Drugs Market Drivers Table 14. Direct-acting Antiviral Drugs Market Challenges Table 15. Direct-acting Antiviral Drugs Market Restraints Table 16. Global Direct-acting Antiviral Drugs Revenue by Players (2016-2021) & (US$ Million) Table 17. Global Direct-acting Antiviral Drugs Market Share by Players (2016-2021) Table 18. Global Top Direct-acting Antiviral Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Direct-acting Antiviral Drugs as of 2020) Table 19. Ranking of Global Top Direct-acting Antiviral Drugs Companies by Revenue (US$ Million) in 2020 Table 20. Global 5 Largest Players Market Share by Direct-acting Antiviral Drugs Revenue (CR5 and HHI) & (2016-2021) Table 21. Key Players Headquarters and Area Served Table 22. Key Players Direct-acting Antiviral Drugs Product Solution and Service Table 23. Date of Enter into Direct-acting Antiviral Drugs Market Table 24. Mergers & Acquisitions, Expansion Plans Table 25. Global Direct-acting Antiviral Drugs Market Size by Type (2016-2021) (US$ Million) Table 26. Global Direct-acting Antiviral Drugs Revenue Market Share by Type (2016-2021) Table 27. Global Direct-acting Antiviral Drugs Forecasted Market Size by Type (2022-2027) (US$ Million) Table 28. Global Direct-acting Antiviral Drugs Revenue Market Share by Type (2022-2027) & (US$ Million) Table 29. Global Direct-acting Antiviral Drugs Market Size Share by Application (2016-2021) & (US$ Million) Table 30. Global Direct-acting Antiviral Drugs Revenue Market Share by Application (2016-2021) Table 31. Global Direct-acting Antiviral Drugs Forecasted Market Size by Application (2022-2027) (US$ Million) Table 32. Global Direct-acting Antiviral Drugs Revenue Market Share by Application (2022-2027) & (US$ Million) Table 33. North America Direct-acting Antiviral Drugs Market Size by Type (2016-2021) (US$ Million) Table 34. North America Direct-acting Antiviral Drugs Market Size by Type (2022-2027) & (US$ Million) Table 35. North America Direct-acting Antiviral Drugs Market Size by Application (2016-2021) (US$ Million) Table 36. North America Direct-acting Antiviral Drugs Market Size by Application (2022-2027) & (US$ Million) Table 37. North America Direct-acting Antiviral Drugs Market Size by Country (2016-2021) & (US$ Million) Table 38. North America Direct-acting Antiviral Drugs Market Size by Country (2022-2027) & (US$ Million) Table 39. Europe Direct-acting Antiviral Drugs Market Size by Type (2016-2021) (US$ Million) Table 40. Europe Direct-acting Antiviral Drugs Market Size by Type (2022-2027) & (US$ Million) Table 41. Europe Direct-acting Antiviral Drugs Market Size by Application (2016-2021) (US$ Million) Table 42. Europe Direct-acting Antiviral Drugs Market Size by Application (2022-2027) & (US$ Million) Table 43. Europe Direct-acting Antiviral Drugs Market Size by Country (2016-2021) & (US$ Million) Table 44. Europe Direct-acting Antiviral Drugs Market Size by Country (2022-2027) & (US$ Million) Table 45. Asia-Pacific Direct-acting Antiviral Drugs Market Size by Type (2016-2021) (US$ Million) Table 46. Asia-Pacific Direct-acting Antiviral Drugs Market Size by Type (2022-2027) & (US$ Million) Table 47. Asia-Pacific Direct-acting Antiviral Drugs Market Size by Application (2016-2021) (US$ Million) Table 48. Asia-Pacific Direct-acting Antiviral Drugs Market Size by Application (2022-2027) & (US$ Million) Table 49. Asia-Pacific Direct-acting Antiviral Drugs Market Size by Region (2016-2021) & (US$ Million) Table 50. Asia-Pacific Direct-acting Antiviral Drugs Market Size by Region (2022-2027) & (US$ Million) Table 51. Latin America Direct-acting Antiviral Drugs Market Size by Type (2016-2021) (US$ Million) Table 52. Latin America Direct-acting Antiviral Drugs Market Size by Type (2022-2027) & (US$ Million) Table 53. Latin America Direct-acting Antiviral Drugs Market Size by Application (2016-2021) (US$ Million) Table 54. Latin America Direct-acting Antiviral Drugs Market Size by Application (2022-2027) & (US$ Million) Table 55. Latin America Direct-acting Antiviral Drugs Market Size by Country (2016-2021) & (US$ Million) Table 56. Latin America Direct-acting Antiviral Drugs Market Size by Country (2022-2027) & (US$ Million) Table 57. Middle East & Africa Direct-acting Antiviral Drugs Market Size by Type (2016-2021) (US$ Million) Table 58. Middle East & Africa Direct-acting Antiviral Drugs Market Size by Type (2022-2027) & (US$ Million) Table 59. Middle East & Africa Direct-acting Antiviral Drugs Market Size by Application (2016-2021) (US$ Million) Table 60. Middle East & Africa Direct-acting Antiviral Drugs Market Size by Application (2022-2027) & (US$ Million) Table 61. Middle East & Africa Direct-acting Antiviral Drugs Market Size by Country (2016-2021) & (US$ Million) Table 62. Middle East & Africa Direct-acting Antiviral Drugs Market Size by Country (2022-2027) & (US$ Million) Table 63. AbbVie Inc. Company Details Table 64. AbbVie Inc. Business Overview Table 65. AbbVie Inc. Direct-acting Antiviral Drugs Product Table 66. AbbVie Inc. Revenue in Direct-acting Antiviral Drugs Business (2016-2021) & (US$ Million) Table 67. AbbVie Inc. Recent Development Table 68. GSK Company Details Table 69. GSK Business Overview Table 70. GSK Direct-acting Antiviral Drugs Product Table 71. GSK Revenue in Direct-acting Antiviral Drugs Business (2016-2021) & (US$ Million) Table 72. GSK Recent Development Table 73. Boehringer Ingelheim Company Details Table 74. Boehringer Ingelheim Business Overview Table 75. Boehringer Ingelheim Direct-acting Antiviral Drugs Product Table 76. Boehringer Ingelheim Revenue in Direct-acting Antiviral Drugs Business (2016-2021) & (US$ Million) Table 77. Boehringer Ingelheim Recent Development Table 78. Merck Company Details Table 79. Merck Business Overview Table 80. Merck Direct-acting Antiviral Drugs Product Table 81. Merck Revenue in Direct-acting Antiviral Drugs Business (2016-2021) & (US$ Million) Table 82. Merck Recent Development Table 83. Novartis Company Details Table 84. Novartis Business Overview Table 85. Novartis Direct-acting Antiviral Drugs Product Table 86. Novartis Revenue in Direct-acting Antiviral Drugs Business (2016-2021) & (US$ Million) Table 87. Novartis Recent Development Table 88. Beximco Pharmaceuticals Company Details Table 89. Beximco Pharmaceuticals Business Overview Table 90. Beximco Pharmaceuticals Direct-acting Antiviral Drugs Product Table 91. Beximco Pharmaceuticals Revenue in Direct-acting Antiviral Drugs Business (2016-2021) & (US$ Million) Table 92. Beximco Pharmaceuticals Recent Development Table 93. Roche Company Details Table 94. Roche Business Overview Table 95. Roche Direct-acting Antiviral Drugs Product Table 96. Roche Revenue in Direct-acting Antiviral Drugs Business (2016-2021) & (US$ Million) Table 97. Roche Recent Development Table 98. Bristol-Myers Squibb Company Company Details Table 99. Bristol-Myers Squibb Company Business Overview Table 100. Bristol-Myers Squibb Company Revenue in Direct-acting Antiviral Drugs Business (2016-2021) & (US$ Million) Table 101. Bristol-Myers Squibb Company Recent Development Table 102. Gilead Sciences Company Details Table 103. Gilead Sciences Business Overview Table 104. Gilead Sciences Direct-acting Antiviral Drugs Product Table 105. Gilead Sciences Revenue in Direct-acting Antiviral Drugs Business (2016-2021) & (US$ Million) Table 106. Gilead Sciences Recent Development Table 107. Janssen (Johnson & Johnson) Company Details Table 108. Janssen (Johnson & Johnson) Business Overview Table 109. Janssen (Johnson & Johnson) Direct-acting Antiviral Drugs Product Table 110. Janssen (Johnson & Johnson) Revenue in Direct-acting Antiviral Drugs Business (2016-2021) & (US$ Million) Table 111. Janssen (Johnson & Johnson) Recent Development Table 112. Vertex Pharmaceuticals Company Details Table 113. Vertex Pharmaceuticals Business Overview Table 114. Vertex Pharmaceuticals Direct-acting Antiviral Drugs Product Table 115. Vertex Pharmaceuticals Revenue in Direct-acting Antiviral Drugs Business (2016-2021) & (US$ Million) Table 116. Vertex Pharmaceuticals Recent Development Table 117. Natco Pharma Company Details Table 118. Natco Pharma Business Overview Table 119. Natco Pharma Direct-acting Antiviral Drugs Product Table 120. Natco Pharma Revenue in Direct-acting Antiviral Drugs Business (2016-2021) & (US$ Million) Table 121. Natco Pharma Recent Development Table 122. Research Programs/Design for This Report Table 123. Key Data Information from Secondary Sources Table 124. Key Data Information from Primary Sources List of Figures Figure 1. Global Direct-acting Antiviral Drugs Market Share by Type: 2020 VS 2027 Figure 2. NS3/4A Protease Inhibitors Features Figure 3. Nucleoside and Nucleotide NS5B Polymerase Inhibitors Features Figure 4. NS5A Inhibitors Features Figure 5. Non-Nucleoside NS5B Polymerase Inhibitors Features Figure 6. Global Direct-acting Antiviral Drugs Market Share by Application: 2020 VS 2027 Figure 7. Hospitals Case Studies Figure 8. Clinics Case Studies Figure 9. Ambulatory Surgical Centers Case Studies Figure 10. Pharmacies Case Studies Figure 11. Others Case Studies Figure 12. Direct-acting Antiviral Drugs Report Years Considered Figure 13. Global Direct-acting Antiviral Drugs Market Size (US$ Million), Year-over-Year: 2016-2027 Figure 14. Global Direct-acting Antiviral Drugs Market Size (US$ Million), 2016 VS 2021 VS 2027 Figure 15. Global Direct-acting Antiviral Drugs Market Share by Regions: 2020 VS 2027 Figure 16. Global Direct-acting Antiviral Drugs Market Share by Regions (2022-2027) Figure 17. Global Direct-acting Antiviral Drugs Market Share by Players in 2020 Figure 18. Global Top Direct-acting Antiviral Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Direct-acting Antiviral Drugs as of 2020 Figure 19. The Top 10 and 5 Players Market Share by Direct-acting Antiviral Drugs Revenue in 2020 Figure 20. Global Direct-acting Antiviral Drugs Revenue Market Share by Type (2016-2021) Figure 21. Global Direct-acting Antiviral Drugs Revenue Market Share by Type (2022-2027) Figure 22. North America Direct-acting Antiviral Drugs Market Size YoY Growth (2016-2027) & (US$ Million) Figure 23. North America Direct-acting Antiviral Drugs Market Share by Type (2016-2027) Figure 24. North America Direct-acting Antiviral Drugs Market Share by Application (2016-2027) Figure 25. North America Direct-acting Antiviral Drugs Market Share by Country (2016-2027) Figure 26. United States Direct-acting Antiviral Drugs Market Size YoY Growth (2016-2027) & (US$ Million) Figure 27. Canada Direct-acting Antiviral Drugs Market Size YoY Growth (2016-2027) & (US$ Million) Figure 28. Europe Direct-acting Antiviral Drugs Market Size YoY Growth (2016-2027) & (US$ Million) Figure 29. Europe Direct-acting Antiviral Drugs Market Share by Type (2016-2027) Figure 30. Europe Direct-acting Antiviral Drugs Market Share by Application (2016-2027) Figure 31. Europe Direct-acting Antiviral Drugs Market Share by Country (2016-2027) Figure 32. Germany Direct-acting Antiviral Drugs Market Size YoY Growth (2016-2027) & (US$ Million) Figure 33. France Direct-acting Antiviral Drugs Market Size YoY Growth (2016-2027) & (US$ Million) Figure 34. U.K. Direct-acting Antiviral Drugs Market Size YoY Growth (2016-2027) & (US$ Million) Figure 35. Italy Direct-acting Antiviral Drugs Market Size YoY Growth (2016-2027) & (US$ Million) Figure 36. Russia Direct-acting Antiviral Drugs Market Size YoY Growth (2016-2027) & (US$ Million) Figure 37. Nordic Direct-acting Antiviral Drugs Market Size YoY Growth (2016-2027) & (US$ Million) Figure 38. Asia-Pacific Direct-acting Antiviral Drugs Market Size YoY Growth (2016-2027) & (US$ Million) Figure 39. Asia-Pacific Direct-acting Antiviral Drugs Market Share by Type (2016-2027) Figure 40. Asia-Pacific Direct-acting Antiviral Drugs Market Share by Application (2016-2027) Figure 41. Asia-Pacific Direct-acting Antiviral Drugs Market Share by Region (2016-2027) Figure 42. China Direct-acting Antiviral Drugs Market Size YoY Growth (2016-2027) & (US$ Million) Figure 43. Japan Direct-acting Antiviral Drugs Market Size YoY Growth (2016-2027) & (US$ Million) Figure 44. South Korea Direct-acting Antiviral Drugs Market Size YoY Growth (2016-2027) & (US$ Million) Figure 45. Southeast Asia Direct-acting Antiviral Drugs Market Size YoY Growth (2016-2027) & (US$ Million) Figure 46. India Direct-acting Antiviral Drugs Market Size YoY Growth (2016-2027) & (US$ Million) Figure 47. Australia Direct-acting Antiviral Drugs Market Size YoY Growth (2016-2027) & (US$ Million) Figure 48. Latin America Direct-acting Antiviral Drugs Market Size YoY Growth (2016-2027) & (US$ Million) Figure 49. Latin America Direct-acting Antiviral Drugs Market Share by Type (2016-2027) Figure 50. Latin America Direct-acting Antiviral Drugs Market Share by Application (2016-2027) Figure 51. Latin America Direct-acting Antiviral Drugs Market Share by Country (2016-2027) Figure 52. Mexico Direct-acting Antiviral Drugs Market Size YoY Growth (2016-2027) & (US$ Million) Figure 53. Brazil Direct-acting Antiviral Drugs Market Size YoY Growth (2016-2027) & (US$ Million) Figure 54. Middle East & Africa Direct-acting Antiviral Drugs Market Size YoY Growth (2016-2027) & (US$ Million) Figure 55. Middle East & Africa Direct-acting Antiviral Drugs Market Share by Type (2016-2027) Figure 56. Middle East & Africa Direct-acting Antiviral Drugs Market Share by Application (2016-2027) Figure 57. Middle East & Africa Direct-acting Antiviral Drugs Market Share by Country (2016-2027) Figure 58. Turkey Direct-acting Antiviral Drugs Market Size YoY Growth (2016-2027) & (US$ Million) Figure 59. Saudi Arabia Direct-acting Antiviral Drugs Market Size YoY Growth (2016-2027) & (US$ Million) Figure 60. UAE Direct-acting Antiviral Drugs Market Size YoY Growth (2016-2027) & (US$ Million) Figure 61. AbbVie Inc. Revenue Growth Rate in Direct-acting Antiviral Drugs Business (2016-2021) Figure 62. GSK Revenue Growth Rate in Direct-acting Antiviral Drugs Business (2016-2021) Figure 63. Boehringer Ingelheim Revenue Growth Rate in Direct-acting Antiviral Drugs Business (2016-2021) Figure 64. Merck Revenue Growth Rate in Direct-acting Antiviral Drugs Business (2016-2021) Figure 65. Novartis Revenue Growth Rate in Direct-acting Antiviral Drugs Business (2016-2021) Figure 66. Beximco Pharmaceuticals Revenue Growth Rate in Direct-acting Antiviral Drugs Business (2016-2021) Figure 67. Roche Revenue Growth Rate in Direct-acting Antiviral Drugs Business (2016-2021) Figure 68. Bristol-Myers Squibb Company Revenue Growth Rate in Direct-acting Antiviral Drugs Business (2016-2021) Figure 69. Gilead Sciences Revenue Growth Rate in Direct-acting Antiviral Drugs Business (2016-2021) Figure 70. Janssen (Johnson & Johnson) Revenue Growth Rate in Direct-acting Antiviral Drugs Business (2016-2021) Figure 71. Vertex Pharmaceuticals Revenue Growth Rate in Direct-acting Antiviral Drugs Business (2016-2021) Figure 72. Natco Pharma Revenue Growth Rate in Direct-acting Antiviral Drugs Business (2016-2021) Figure 73. Bottom-up and Top-down Approaches for This Report Figure 74. Data Triangulation Figure 75. Key Executives Interviewed

AbbVie Inc. GSK Boehringer Ingelheim Merck Novartis Beximco Pharmaceuticals Roche Bristol-Myers Squibb Company Gilead Sciences Janssen (Johnson & Johnson) Vertex Pharmaceuticals Natco Pharma